EWA
LUCD icon

EverSource Wealth Advisors’s Lucid Diagnostics LUCD Stock Holding History

EverSource Wealth Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86K Buy
1,738
+1,339
+336% +$1.44K ﹤0.01% 3749
2026
Q1 		$459 Buy
+399
New +$508 ﹤0.01% 4082

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

EverSource Wealth Advisors's LUCD Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Lucid Diagnostics (LUCD) stake by 336% in Q2 2026, buying an estimated $1.44K and bringing the position to 1,738 shares worth $1.86K. The position accounts for ﹤0.01% of the portfolio, ranked #3749.

EverSource Wealth Advisors first reported a position in LUCD in Q1 2026 and has held it in 2 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • EverSource Wealth Advisors held 1,738 shares of Lucid Diagnostics worth $1.86K as of Q2 2026.
  • EverSource Wealth Advisors bought 1,339 Lucid Diagnostics shares in Q2 2026, an estimated $1.44K.
  • Lucid Diagnostics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3749 holding.
  • EverSource Wealth Advisors first reported a position in Lucid Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.